Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 3/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 14/20 | 0.48 |
| ▸ | FLT1 | P17948 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 7/20 | 0.48 |
| ▸ | KIF5B | P33176 | 5/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535303 | 0.84 | EGFR (0.59) | EGFRSRCRAF1BRAFKDR | |
| SCHEMBL535262 | 0.81 | KDR (0.49) | EGFRSRCRAF1BRAFKDR | |
| SCHEMBL535365 | 0.80 | EGFR (0.50) | EGFRSRCRAF1BRAFKDR | |
| SCHEMBL535332 | 0.80 | RET (0.48) | EGFRSRCKDRFLT1FGFR1 | |
| SCHEMBL535127 | 0.78 | EGFR (0.66) | EGFRRAF1BRAFKDRFLT1 | |
| SCHEMBL3958826 | 0.77 | EGFR (0.62) | EGFRSRCRAF1BRAFKDR | |
| SCHEMBL13438440 | 0.76 | EGFR (0.52) | EGFRSRCRAF1BRAFKDR | |
| SCHEMBL535118 | 0.75 | EGFR (0.49) | EGFRSRCRAF1BRAFKDR | |
| SCHEMBL535218 | 0.75 | KDR (0.53) | EGFRSRCRAF1BRAFKDR | |
| SCHEMBL13404542 | 0.75 | EGFR (0.56) | EGFRSRCRAF1BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | disclosed |
| EP-1633365-B1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2305687-A1 | Quinazoline derivatives | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-7648975-B2 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| EP-1633365-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105765-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | NR1H3, NR1H2, NCOA3 | EGFR 684/4885SRC 1732/4885RAF1 2467/4885 |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | EGFR 1503/4885SRC 2917/4885RAF1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.